Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacy-Based hepatitis c testing could cure more people on opioid therapy

NCT ID NCT03935906

Completed Disease control Sponsor: University of Dundee Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether offering hepatitis C testing right in community pharmacies—using a simple finger-prick device—helps more people on opioid therapy get diagnosed and cured compared to the usual approach of referring them to a clinic. Participants are adults on stable methadone or buprenorphine treatment who have a history of injecting drug use. Those who test positive receive a highly effective 8- to 24-week course of antiviral pills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
direct-acting antiviral treatment (glecaprevir/pibrentasvir) for hepatitis C
What this could lead to
If successful, this approach could dramatically increase hepatitis C testing and cure rates among people on opioid therapy, helping eliminate the virus in a high-risk group.
What could go wrong
The trial focuses on a specific population and setting, so results may not apply broadly. Also, the intervention relies on nurse availability and patient willingness to engage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C

Contacts and locations

Locations

  • NHS Tayside

    Dundee, Scotland, United Kingdom

  • Public Health Wales

    Cardiff, Wales, United Kingdom

  • The Burnet Institute

    Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.